Modality
Fusion Protein
MOA
GLP-1/GIP
Target
WRN
Pathway
Neuroinflam
RSV
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
~Dec 2019
→ ~Mar 2021
NDA/BLA
Jun 2021
→ Nov 2031
NDA/BLACurrent
NCT07624186
354 pts·RSV
2023-10→2027-10·Completed
NCT04681928
1,292 pts·RSV
2021-06→2031-11·Completed
1,646 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-081.5y awayPh3 Readout· RSV
2031-11-165.6y awayPh3 Readout· RSV
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Complet…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2027-10-08 · 1.5y away
RSV
Ph3 Readout
2031-11-16 · 5.6y away
RSV
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07624186 | NDA/BLA | RSV | Completed | 354 | FEV1 |
| NCT04681928 | NDA/BLA | RSV | Completed | 1292 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK |